fashion -WSS

fashion

author：entertainment 2025-10-01 20:14:32 - browse：1353

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

What affirmative action's end means to a medical student

‘The Bear’ and hospitality in hospitals

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Lessons Learned: This is why you network to find that industry job you want

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Activists slam private health insurers over coverage restrictions

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Medicare proposal to cover medical devices draws a mixed reaction

Canadians with cystic fibrosis outlive Americans by a decade

Peter Hotez and the public health issue of online harassment

Beware reading your test results before your doctor does

State Dept. review finds Biden bears some blame for Afghanistan failures

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Wikipedia

Fatty liver disease was alleviated by Lilly’s ‘triple

Astronauts get first look at the spacecraft that will fly them around the moon

Dexcom's push to bring CGM to type 2 diabetes patients

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

entertainment

knowledge

entertainment

focus